Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly
- 24 July 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Reviews in Endocrine and Metabolic Disorders
- Vol. 20 (3), 365-381
- https://doi.org/10.1007/s11154-019-09506-y
Abstract
Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion from a somatotroph pituitary adenoma. GH hypersecretion leads to overproduction of insulin-like growth factor-1 (IGF-1), which contributes to the somatic overgrowth, physical disfigurement, onset of multiple systemic comorbidities, reduced quality of life (QoL) and premature mortality of uncontrolled patients. Somatostatin receptor ligands, dopamine agonists and a GH receptor antagonist are currently available for medical therapy of acromegaly. The main aim of treatment is biochemical normalisation, defined as age-normalised serum IGF-1 values and random GH levels <1.0 μg/L. However, there is an increasing evidence suggesting that achieving biochemical control does not always decrease the burden of disease-related comorbidities and/or improve patients’ QoL. This lack of correlation between biochemical and clinical control can be due to both disease duration (late diagnosis) or to the peculiarity of a given comorbidity. Herein we conducted ad hoc literature searches in order to find the most recent and relevant reports on biochemical and clinical disease control during medical treatment of acromegaly. Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.Keywords
This publication has 145 references indexed in Scilit:
- Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Clinical, quality of life, and economic value of acromegaly disease controlPituitary, 2011
- Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the diseaseActa Endocrinologica, 2008
- GH and IGF‐I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatmentClinical Endocrinology, 2008
- Growth Hormone, Insulin-Like Growth Factors, and the SkeletonEndocrine Reviews, 2008
- Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegalyActa Endocrinologica, 2007
- Treatment of acromegaly improves quality of life, measured by AcroQolClinical Endocrinology, 2007
- Late potentials and ventricular arrhythmias in acromegalyInternational Journal of Cardiology, 2005
- Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF systemClinical Endocrinology, 2004
- Insulin like growth factor 1 increases vascular smooth muscle nitric oxide productionLife Sciences, 1997